Crosstree

How is AI reshaping the future of clinical trials? Crosstree's Shane Senior recently presented during SCOPE's partnering summit on the transformative role AI is playing in trial design, patient recruitment, and data analysis—accelerating timelines and improving patient outcomes. At Crosstree, we continue to track these advancements and their implications for M&A activity in the health sciences ecosystem. Read this recap for highlights from the presentation: https://hubs.li/Q037lh3G0 #ClinicalTrials #AI #LifeSciences #MergersAndAcquisitions #privateequity Cambridge VIP: Venture, Innovation & Partnering

Planning on attending ViVE in Nashville next week? Connect with us on site! We’re eager to connect with top professionals, including C-suite executives, senior digital health leaders and buyers, health startups and investors, and policymakers. Connect with our team on site by filling out this form: https://hubs.li/Q036MddD0 #ViVE2025 #ClinicalResearch #investmentbanking

The proteomics market is projected to grow from $31.6B in 2024 to $94.7B by 2035 (10.5% CAGR), driven by advances in personalized medicine, cancer immunotherapy, and autoimmune treatments. Sengenics, a leader in immuno-proteomics, specializes in protein-binding applications and disease profiling. Its proprietary Krex protein folding technology enables precise protein interactions, critical for biomarker discovery and precision medicine. Recognizing this value, Standard BioTools acquired Sengenics, expanding its capabilities in immuno-proteomics and global research. Crosstree acted as the exclusive financial advisor to Sengenics in this transaction. Read more about the transaction here: https://hubs.li/Q03694-g0 #pharma #MandA #investmentbanking #biotech Greg Bare

Healthcare technology M&A remains highly dynamic, driven by demand for innovation in diagnostics, personalized medicine, and data-driven solutions. Biomarker advancements are central to this shift, enabling precision medicine and targeted therapies. ActiGraph is a leading provider of wearable activity monitoring solutions, specializing in generating real-world, patient-centric data for clinical trials and health research. With their advanced biosensors and analytics platform, this enables precise tracking of biomarkers, making them a pivotal player in the evolving healthcare technology market. In the strategic move to acquire Biofourmis, a global leader in digital health, leveraging AI-driven predictive analytics and wearable biosensors allows ActiGraph to expand their technology platforms and capabilities to give them full, comprehensive solutions in drug development. Crosstree acted as the exclusive financial advisor to Actigraph in this transaction. Read more about this #acquisition in our Deal Insights: https://hubs.li/Q035qThG0 #pharma #pharmaceuticalindustry #mergersandacquisitions #investmentbanking Greg Bare

Congratulations to Sengenics on its acquisition by Standard BioTools to broaden its capabilities in proteomics and immunology research. To close our 38th cross-border transaction and our 68th diagnostics and tools deal, Crosstree helped Sengenics identify Standard BioTools as the ideal partner through: 📑Evaluating a broad slate of potential financial and strategic partners 🔍Helping clients find the right partner to accelerate their growth globally ⏲️Managing the due diligence process timeline to bring the transaction to a successful outcome Read the full Deal Insights here: https://hubs.li/Q034Yn2K0 #pharma #pharmaceuticalindustry #mergersandacquisitions #investmentbanking Greg Bare

Announcing our new Pharma Services - Pharmaceutical Commerce BlueBook! Whether you're strategizing your next move or seeking to understand market shifts, the BlueBook is your go-to resource for informed decision-making. Highlights from the December edition include: 📌Realyze Intelligence was acquired by Carta Healthcare 📌Kester Capital announced its acquisition of Emas Pharma 📌Cleerly closed a $298 Series A Financing, led by Battery Ventures, Insight Venture Management, and LRVHealth Want to read more? Click the link below: https://hubs.li/Q034LrDT0 #Insights #MergersAndAcquisitions #PrivateEquity #FinancialNews #PharmaServices

Congratulations to Bio-Techne on the divestiture of assets of its subsidiary, Atlanta Biologicals, to GeminiBio! To close our 69th diagnostics and tools transaction, Crosstree helped Bio-Techne identify GeminiBio as the ideal partner through: 📑Evaluating a select universe of potential strategic partners 🔍Navigating various alternatives with a primary objective of continuity of quality product for customers 💡Leveraging market expertise within cell culture to identify potential synergies via combination Read the full Deal Insights here: https://hubs.li/Q034tK-90 #diagnostics&tools #mergersandacquisitions #investmentbanking Jeff Ellis

Are you attending #SCOPE2025? Join Crosstree's Shane Senior, Managing Director and Co-Founder, for a keynote presentation on "Shaping Tomorrow's Clinical Trial Market Today: Deal Trends and AI's Role" on Wednesday, February 5, at 9:10 AM. The clinical trial market is undergoing a profound transformation, fueled by tech-enabled services and the growing influence of AI. Shane will explore how past investments and acquisitions have shaped the industry and reveal key investing strategies for future value creation. Learn how #AI is both a game-changing opportunity and a potential threat—one that will define winning and losing strategies in this rapidly evolving space. Click the link to view the full SCOPE Partnering event agenda: https://hubs.li/Q034jD-30 We look forward to seeing you there! #SCOPE2025 #ClinicalResearch #investmentbanking #privateequity Cambridge Healthtech Institute

Congratulations to Crosstree's Greg Bare on his promotion to Managing Director! Greg has consistently exemplified the values of leadership, collaboration, and excellence, making a significant impact on our clients and our team. His deep expertise and strategic insights have been invaluable in advancing our mission of delivering exceptional advisory services in the health sciences space. As Managing Director, Greg will take on an even greater role in guiding our clients and shaping the future of Crosstree. Please join us in celebrating Greg’s achievement and wishing him continued success in this new chapter! Learn more about our leadership team here: https://hubs.li/Q033D-K-0 #investmentbanking #lifesciences #bankingcareers #banking

#NowHiring for Analyst II & III positions! We are seeking talented professionals to join our team. Based in Tampa, FL, we’ve completed over 200 transactions in pharmaceutical services, diagnostics, and healthcare technology, advising on deals from $25M to $1B. What You’ll Do: 📈 Build financial models and perform valuation analyses. 🔍 Track industry trends and M&A activity. 📊 Contribute to client presentations and due diligence efforts. What We’re Looking For: 📌 2–3 years of investment banking/M&A experience. 📌 Strong analytical, communication, and organizational skills. 📌 Bachelor’s degree in finance, accounting, or business (Series 63 & 79 required). If you are passionate about driving impactful results and advancing your career in a challenging yet rewarding environment, we encourage you to apply directly at the link below: https://hubs.li/Q033VHnr0 #investmentbanking #lifesciences #bankingcareers #banking